Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical alendronic acid (Soludronate) for alveolar bone remodeling after tooth extraction
2021-005511-32Phase 3Active
- Sponsor
- Xeolas Pharmaceuticals
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alveolar bone atrophy (ABL) and gingival disease comparing Soludronate topical treatment with Placebo topical treatment (2 arms). Primary endpoints: Buccal and lingual vertical and horizontal bone socket dimensions and Three-dimensional volumetric changes in hard tissue. Started Mar 2022; status: active.
02
Drugs
Soludronate
03
Conditions
Alveolar bone atrophy (ABL)gingival disease
Beyond the preview
Go deeper on 2021-005511-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005511-32.